Pantop%25252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. ## Primary Indications * Short-term treatment of erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Prophylaxis of stress-related mucosal injury (off-label use common in ICU). ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg PO/IV once daily for 8 weeks; may continue for another 8 weeks if necessary. * **Maintenance of Healing:** 40 mg PO once daily. * **Hypersecretory Conditions:** Starting dose 40 mg PO/IV twice daily. Doses up to 240 mg/day have been used; titrate based on acid output measurements. ## Pediatric Dosing * **GERD/Erosive Esophagitis (5 years and older):** * 15 kg to <40 kg: 20 mg PO once daily for up to 8 weeks. * $\ge$ 40 kg: 40 mg PO once daily for up to 8 weeks. * **IV Dosing:** Safety and efficacy in pediatric patients for IV administration have not been established. ## Dose Adjustments * **Hepatic Impairment:** Reduce dose in severe hepatic impairment (Child-Pugh C). While no strict standardized reduction exists, clinical practice often limits the dose to 20 mg daily or every other day. * **Renal Impairment:** No dosage adjustment necessary. * **Elderly:** No dosage adjustment required based on age alone. ## Contraindications * Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole). * Combined use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, fractures (hip, wrist, spine), and cutaneous/systemic lupus erythematosus. ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic gastric pH (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil). * **CYP2C19 Inhibitors/Inducers:** Pantoprazole is primarily metabolized by CYP2C19. Interactions with strong inhibitors (e.g., fluconazole, fluvoxamine) may increase exposure. * **Methotrexate:** High-dose methotrexate serum levels may increase when taken with PPIs. ## Monitoring * **Symptom relief:** Monitor for clinical response; re-evaluate if symptoms persist or worsen. * **Long-term use:** Monitor magnesium levels and vitamin B12 levels periodically if on therapy >1 year. * **Renal:** Monitor for signs of interstitial nephritis. ## Clinical Pearls * **Administration:** PO tablets should be swallowed whole; do not crush, split, or chew. Can be taken with or without food. * **IV Administration:** When converting from IV to PO, the switch should be made as soon as the patient can tolerate oral medications. * **Deprescribing:** Attempt to taper or discontinue PPIs if maintenance therapy is no longer clinically indicated to avoid long-term risks. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical protocols may vary by institution. Always verify dosages, contraindications, and drug interactions against current, authoritative local resources (e.g., institutional formulary, Lexicomp, or UpToDate) and the official FDA-approved package insert before prescribing or administering medication.